Best Northern Mariana Islands Grants for Nonprofits

The Intervention Research to Improve Native American Health (R21 Clinical Trials Optional) aims to support exploratory studies focused on enhancing health outcomes within Native American populations. This initiative encourages research that addresses critical health disparities, tests new interventions, and develops culturally appropriate solutions to improve health and well-being. Applications are encouraged to include community-driven research, addressing unique sociopolitical and environmental challenges faced by these populations, ultimately aiming to reduce morbidity and mortality.

The NCI Worta McCaskill-Stevens Career Development Award supports new clinicians committed to research in community oncology and cancer prevention. This funding aims to facilitate their transition to independent research careers and advanced funding mechanisms. Scholars can lead independent community-based clinical trials, conduct ancillary studies, or gain valuable research experience, specifically targeting underserved communities. Applications are due by 5:00 PM local time of the applicant's organization.

This grant opportunity aims to reduce sleep health disparities through non-pharmacological interventions. It supports research that examines sleep as a modifiable factor influencing health outcomes among populations facing health disparities. The initiative highlights the importance of promoting sleep health in various communities, ensuring equitable access to resources and interventions. Deadlines for applications span from October 2024 to June 2027, allowing multiple opportunities for researchers to apply and contribute to this vital area of health research.

The NIH Countermeasures Against Chemical Threats (CounterACT) initiative invites applications for basic research on chemical agents affecting the nervous system. This program aims to explore the toxicity mechanisms of chemical warfare agents, industrial chemicals, and pesticides. Researchers are encouraged to generate data that could reveal new therapeutic targets and manifestations of toxic exposures, contributing to public health safety against potential chemical threats.

The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for research on isolated human islets as a diabetes treatment. This initiative aims to gather data from clinical trials, aiding the research community in future publications and trial designs. While applications are not currently being accepted, potential applicants are encouraged to start forming collaborations and consider applying when the opportunity opens.

The Animal and Veterinary Innovation Centers (U18) funding opportunity, led by the FDA, aims to foster collaborations with academic institutions to tackle critical veterinary health challenges. This includes addressing Highly Pathogenic Avian Influenza, promoting genomic advancements in agriculture, and developing veterinary solutions for minor species. Applications are invited to enhance animal health and public safety, with Letters of Intent due prior to the July 2024 deadline.

The FY26 Tick-Borne Disease Research Program (TBDRP) Idea Development Award aims to fund innovative research that enhances understanding and treatment of Lyme disease and other tick-borne diseases. The program encourages creative approaches that challenge existing paradigms and fosters impactful discoveries. A special career development option is available for early-career investigators, offering mentorship and a tailored review process to support significant research advancements.

The FY26 Tick-Borne Disease Research Program (TBDRP) Therapeutic/Diagnostic Research Award aims to foster innovative therapeutic and diagnostic research for Lyme disease and other tick-borne conditions. This award supports early-stage drug discovery and evaluation studies, as well as novel diagnostic methods that can be seamlessly implemented in clinical environments, ultimately enhancing patient care and quality of life.

The FY26 Pancreatic Cancer Research Program (PCARP) Idea Development Award promotes innovative, high-risk research aimed at significant advancements for pancreatic cancer outcomes. This award supports projects with preliminary data, focusing on impactful discoveries. It features a Partnering Principal Investigator option, enhancing funding for collaborations between experienced mentors and early-career researchers. All applications must align with the FY26 PCARP Focus Areas, ensuring relevance and potential for transformative results in pancreatic cancer research.

The Mobile Learning Fund provides grants to adult literacy programs in the U.S. and Canada, enabling access to digital learning solutions. These grants support various online learning tools, such as New Readers Press, Learning Upgrade, and EnGen, aimed at enhancing literacy, math, and digital skills. Eligible programs must implement the solutions within 30 days and ensure active learner engagement. This initiative empowers educators to expand their reach and improve student outcomes through innovative digital resources.

The Innovative Programs to Enhance Research Training (IPERT) initiative by the NIH aims to support innovative educational activities that enhance the skills of participants across various career stages in the biomedical research field. This program focuses on courses for skills development, mentoring activities, and curriculum or methods development, ensuring a robust structure for leadership, recruitment, and evaluation.

The Ryan White HIV/AIDS Program Part B Supplemental Grant aims to provide essential funding to support HIV care and treatment services across states and territories. This program supplements existing formula-based funding from the RWHAP Part B and ADAP, improving access to necessary resources for those affected by HIV/AIDS. By enhancing support structures, it addresses critical healthcare needs, ensuring better health outcomes for vulnerable populations.

The NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award supports investigator-initiated clinical trials of natural products, including botanicals and dietary supplements. This funding opportunity aims to validate the pharmacokinetics and bioavailability of these products over three years in a phased approach. Successful trials will provide crucial data for further development and clinical application, emphasizing the importance of scientifically driven research in natural product efficacy.

The NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) promotes innovative clinical trials on natural products, such as botanicals and dietary supplements. This funding opportunity supports studies that demonstrate significant scientific rationale and preliminary evidence for efficacy. Applications can explore various delivery methods and combinations with existing treatments to enhance outcomes. Funding is available for up to three years, aimed at bridging basic science discoveries into practical clinical applications.

The NIAID is focused on advancing the research and development of next-generation malaria vaccines, aiming to leverage innovative vaccine design techniques. This initiative not only aims to enhance malaria prevention but also serves as a model for combating other mosquito-borne diseases. By utilizing cutting-edge methods such as structure-based immunogen design and combination vaccines, the program seeks to significantly reduce both parasite infection rates and the overall disease burden associated with malaria.

Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

Hemophilia Fund

Help with healthcare costs for hemophilia

This TotalAssist fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses.

Approved medications

Patient Advocate Foundation covers all the prescription medications for each diagnosis, including generic or bioequivalent drugs, that meet any of the following criteria: FDA-approved, listed in official compendia, and/or listed in published evidence-based or clinical guidelines. See approved medication list for this condition.

Patient Advocate Foundation verifies your diagnosis and treatment plan with your provider directly. We also automatically verify the income eligibility for every applicant. 

Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

Hemophilia Health Equity Fund

Help with healthcare costs for hemophilia (health equity fund)

This TotalAssist fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses.

Health Equity Funds offer help to eligible patients living in areas identified as having increased social and financial needs, as well as higher rates of chronic conditions. Eligibility is determined in part by home address zip code. 

Approved medications

Patient Advocate Foundation covers all the prescription medications for each diagnosis, including generic or bioequivalent drugs, that meet any of the following criteria: FDA-approved, listed in official compendia, and/or listed in published evidence-based or clinical guidelines. See approved medication list for this condition.

Patient Advocate Foundation verifies your diagnosis and treatment plan with your provider directly. We also automatically verify the income eligibility for every applicant. 

Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

Hepatitis C (HepC) Fund

Help with healthcare costs for hepatitis C

This TotalAssist fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses.

Approved medications

Patient Advocate Foundation covers all the prescription medications for each diagnosis, including generic or bioequivalent drugs, that meet any of the following criteria: FDA-approved, listed in official compendia, and/or listed in published evidence-based or clinical guidelines. See approved medication list for this condition.

Patient Advocate Foundation verifies your diagnosis and treatment plan with your provider directly. We also automatically verify the income eligibility for every applicant. 

Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

Hepatitis C (HepC) Health Equity Fund

Help with healthcare costs for hepatitis C (health equity)

This TotalAssist fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses.

Health Equity Funds offer help to eligible patients living in areas identified as having increased social and financial needs, as well as higher rates of chronic conditions. Eligibility is determined in part by home address zip code. 

Approved medications

Patient Advocate Foundation covers all the prescription medications for each diagnosis, including generic or bioequivalent drugs, that meet any of the following criteria: FDA-approved, listed in official compendia, and/or listed in published evidence-based or clinical guidelines. See approved medication list for this condition.

Patient Advocate Foundation verifies your diagnosis and treatment plan with your provider directly. We also automatically verify the income eligibility for every applicant. 

Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

Mucopolysaccharidosis Type III (MPS III) Fund

Help with healthcare costs for mucopolysaccharidosis type III

This TotalAssist fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses. 

Approved medications

Patient Advocate Foundation covers all the prescription medications for each diagnosis, including generic or bioequivalent drugs, that meet any of the following criteria: FDA-approved, listed in official compendia, and/or listed in published evidence-based or clinical guidelines. See approved medication list for this condition.

Patient Advocate Foundation verifies your diagnosis and treatment plan with your provider directly. We also automatically verify the income eligibility for every applicant. 

Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

Mucopolysaccharidosis Type VII (MPS VII) Fund

Help with healthcare costs for mucopolysaccharidosis type VII

This TotalAssist Health Equity Fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses.

Approved medications

Patient Advocate Foundation covers all the prescription medications for each diagnosis, including generic or bioequivalent drugs, that meet any of the following criteria: FDA-approved, listed in official compendia, and/or listed in published evidence-based or clinical guidelines. See approved medication list for this condition.

Patient Advocate Foundation verifies your diagnosis and treatment plan with your provider directly. We also automatically verify the income eligibility for every applicant. 

Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

Mucopolysaccharidosis Type VII (MPS VII) Health Equity Fund

Help with healthcare costs for mucopolysaccharidosis type VII (health equity)

This TotalAssist Health Equity Fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses.

Health Equity Funds offer help to eligible patients living in areas identified as having increased social and financial needs, as well as higher rates of chronic conditions. Eligibility is determined in part by home address zip code.

Approved medications

Patient Advocate Foundation covers all the prescription medications for each diagnosis, including generic or bioequivalent drugs, that meet any of the following criteria: FDA-approved, listed in official compendia, and/or listed in published evidence-based or clinical guidelines. See approved medication list for this condition.

Patient Advocate Foundation verifies your diagnosis and treatment plan with your provider directly. We also automatically verify the income eligibility for every applicant. 

The Fertility Grants (VIVA Program) by the Bob Woodruff Foundation offer vital financial support to wounded veterans facing infertility challenges due to their service-related conditions. Since its inception, the program has assisted over 100 veteran families in starting their own, highlighting a commitment to ensuring veterans have access to necessary fertility treatments. This initiative addresses the unique needs of veterans, recognizing that they experience infertility at nearly double the rate of the general population.

The AHRQ Small Research Projects (R03) program supports short-term research endeavors in primary care, enabling innovative pilot studies, secondary data analysis, and the development of research methodologies. This initiative encourages researchers to explore new technologies and approaches within limited resource frameworks, fostering advancements in healthcare quality and efficiency. Applications are due by 5:00 PM local time of the applicant organization, emphasizing the importance of timely submission.

The National Center for Construction Safety and Health Research and Translation (U54) aims to enhance worker safety in the construction industry through innovative research and intervention strategies. By fostering partnerships and focusing on evidence-based solutions, the Center will address critical safety and health challenges faced by construction workers. The initiative aligns with NIOSH's strategic objectives, promoting collaboration among academic institutions and organizations to improve health outcomes and reduce the occupational health burden in this vital sector.

The Maximizing Investigators’ Research Award (MIRA) for Early Stage Investigators (ESI) by NIGMS aims to enhance research productivity and flexibility for early career scientists. This program consolidates funding into a single award, allowing investigators to pursue ambitious projects while reducing administrative burdens. By supporting diverse research initiatives, MIRA helps cultivate a new generation of innovative researchers, ensuring essential breakthroughs in fundamental science.

The NIH Collaborative International Research Project aims to foster international research collaborations that align with the NIH mission. This grant encourages applications that incorporate at least one international subproject, offering oversight and tracking for NIH-funded international initiatives. Projects should leverage unique resources or populations abroad, contributing to advancements in health sciences relevant to NIH's objectives. This initiative underscores the importance of global partnerships in enhancing research capabilities and outcomes in the United States.